Trial Number



Brain Cancer

Participant Age Range

2 years to 21 years

Participant Gender


Enrolling Participants



A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

There remains a significant unmet medical need for more effective treatment options for pediatric subjects with solid tumors. Overall solid tumors make up to 30% of all cancers in children. Approximately 80% of these tumors are cured with conventional approaches. This is a multicenter, open-label, Phase 1/2 study of lenvatinib in combination with everolimus in pediatric subjects with relapsed or refractory solid tumors. This study will be performed on pediatric subjects with solid tumors, which were resistant to conventional therapy, and for whom there are no alternative therapies that might lead to cure.


Related Clinical Trials

Click on the category you are interested in.